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Type 2 diabetes mellitus confers a threefold increased risk for tuberculosis, but the underlying immunological mechanisms are still
largely unknown. Possiblemediators of this increased susceptibility are short-chain fatty acids, levels ofwhich have been shown to be
altered in individuals with diabetes. We examined the influence of physiological concentrations of butyrate on cytokine responses
to Mycobacterium tuberculosis (Mtb) in human peripheral blood mononuclear cells (PBMCs). Butyrate decreased Mtb-induced
proinflammatory cytokine responses, while it increased production of IL-10. This anti-inflammatory effect was independent of
butyrate’s well-characterised inhibition of HDAC activity and was not accompanied by changes in Toll-like receptor signalling
pathways, the eicosanoid pathway, or cellularmetabolism. In contrast blocking IL-10 activity reversed the effects of butyrate onMtb-
induced inflammation. Alteration of the gut microbiota, thereby increasing butyrate concentrations, can reduce insulin resistance
and obesity, but further studies are needed to determine how this affects susceptibility to tuberculosis.
1. Introduction
Tuberculosis (TB) is the second leading cause of death from
an infectious disease worldwide [1]. Susceptibility to TB can
be increased by several comorbidities, one of which is type
2 diabetes mellitus (DM) [2]. DM patients present with an
overall threefold increased risk of developing active TB [3].
Globally, 15% of TB cases are estimated to be attributable
to DM [4] and thus with a predicted increase of DM by
155% over the next 20 years, DM will become an increasingly
important factor challenging TB control [5–7].
DM patients exhibit alterations in the immune response
against Mycobacterium tuberculosis (Mtb), making them
more susceptible to infection or progression towards active
TB disease and less responsive to treatment [8–11]. How-
ever, the underlying biological mechanisms remain largely
unknown [12, 13]. DMpatients have been associatedwith dys-
regulated cytokine responses toMtb [14–17].Whilst proinfla-
mmatory cytokines are necessary for protection against Mtb,
anti-inflammatory cytokines may counteract these effects.
Possible factors that may impact the host response in patients
with DM are short-chain fatty acids (SCFAs), the main
metabolic products of fermentation of nondigestible dietary
fibres by the gut microbiota. Numerous reports have demon-
strated that DM patients present with an altered composition
of their gut microbiota, which subsequently alters their SCFA
levels [18–24]. SCFAs stronglymodulate immune and inflam-
matory responses [22, 25–31], thereby influencing the host
response to Mtb. SCFAs, of which butyrate (C4) is the most
thoroughly studied, act on immune and endothelial cells via
at least two mechanisms: activation of G-protein coupled
receptors (GPCRs) and inhibition of histone deacetylase
(HDAC) [32]. They affect the function of various cell types
such as lymphocytes [33, 34], neutrophils [25, 31, 35], and
macrophages [28, 36–38]. In light of the emerging role of the
microbiota in inflammation and immunity, we hypothesized
that SCFAs, and in particular butyrate,may affect the immune
response and susceptibility to Mtb in type 2 DM patients.
In this study we investigated the role of physiological
concentrations of SCFAs on the cytokine response against
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Mtb in human peripheral bloodmononuclear cells (PBMCs).
We subsequently examined a number of possiblemechanisms
via which altered concentrations of one particular SCFA,
C4, might affect the host immune response to Mtb in DM
patients. To this purpose, we studied the influence of phys-
iological concentrations of C4 on HDAC activity, immune
signalling pathways, the eicosanoid pathway, and cellular
metabolism. To our knowledge, this is the first study report-
ing on the effects of physiological plasma concentrations of
C4 on Mtb-induced cellular responses. Physiological plasma
concentrations of C4 are in themicromolar range [39], whilst
in previous studies C4 has been used in the millimolar range.
Thus, this study substantially adds to our knowledge of SCFAs
as possible mediators of altered immune responses to Mtb in
DM patients.
2. Materials and Methods
2.1. Human Samples. PBMCs were isolated from buffy coats
donated after written informed consent by healthy volunteers
to the Sanquin Blood Bank (http://www.sanquin.nl/en/) in
Nijmegen. Experiments were conducted according to the
principles expressed in the Declaration of Helsinki. Since
blood donations were anonymous no tuberculosis skin test or
IFN-𝛾 release assay was performed. However, the incidence
of TB in the Dutch population is extremely low (4/100,000),
and Bacillus Calmette-Gue´rin (BCG) vaccination is not part
of the routine vaccination program. Blood donors were not
screened for DM as prevalence of DM among people under
45 years of age (median age of blood donors) is about 1.5%
and therefore DM is unlikely to be a confounding factor [34].
2.2. H37Rv Lysates and Culture. H37Rv Mtb was grown to
mid-log phase in Middlebrook 7H9 liquid medium (Difco,
Becton Dickinson) supplemented with oleic acid/albumin/
dextrose/catalase (OADC) (BBL, Becton Dickinson), washed
three times in sterile saline, heat killed, and then disrupted
using a bead beater, after which the concentration was
measured using a bicinchoninic acid (BCA) assay (Pierce,
Thermo Scientific).
2.3. Cell Stimulation Experiments. Isolation of PBMCs was
performed by differential centrifugation over Ficoll-Paque
(GE Healthcare). Cells were adjusted to 5 × 106 cells/mL
(Beckman Coulter) and suspended in RPMI 1640 (Gibco)
supplemented with 10 𝜇g/mL gentamicin (Lonza), 10mM L-
glutamine (Life Technologies), and 10mM pyruvate (Life
Technologies). 100 𝜇L of PBMCs was incubated in round-
bottom 96-well plates (Greiner), pretreated with SCFAs for
1 h, and stimulated with 1 𝜇g/mL of H37Rv lysate or 10 ng/mL
LPS (Sigma-Aldrich, E. coli serotype 055:B5). Cells were
incubated for 24 h or 7 days at 37∘C in a 5%CO
2
environment
(𝑛 = 6 to 11). Alternatively, PBMCs were pretreated for
1 hour (37∘C, 5% CO
2
) with ranolazine (ITK Diagnostics),
trimetazidine (Sigma), pertussis toxin (Enzo Life Sciences),
etomoxir (Sigma) (inhibitors of 𝛽-oxidation, 𝑛 = 3), aspirin
(Aspe´gic injection powder, 𝑛 = 3), cycloheximide (Sigma,
𝑛 = 6 to 7), anti-IL-10 antibody IgG2a (BioLegend, 𝑛 = 10
to 12), or IgG2a isotype control (BioLegend, 𝑛 = 10 to 12)
prior to stimulation. Cell culture supernatants were collected
and stored at −20∘C for cytokine measurements, performed
by ELISA: TNF-𝛼, IL-1𝛽, IL-17A, IL-22, and IL-1Ra (R&D
Systems) and IL-6, IFN-𝛾, and IL-10 (Sanquin).
2.4. Quantification of Gene Expression. For quantitative real-
time PCR (qPCR) analysis RNA was isolated from PBMCs
using TRIzol reagent (Invitrogen Life Technologies) accord-
ing to the manufacturer’s protocol. RNA was transcribed
into complementary DNA (cDNA) by reverse transcription
using iScript cDNA synthesis kit (Bio-Rad, Hercules, CA).
Primer sequences (Biolegio) are given in Table 1. Power
SYBR Green PCR Master Mix (Applied Biosystems) was
used for qPCR on an AB StepOnePlus real-time PCR system
(Applied Biosystems). qPCR data were normalized to the
housekeeping gene human 𝛽2M (𝑛 = 3 to 10).
2.5. Protein PhosphorylationMeasurements. Western blotting
was carried out using a Trans-Blot Turbo system (Bio-Rad)
according to manufacturer’s instructions. 5 × 106 PBMCs
were lysed in 100 𝜇L lysis buffer.The resulting lysate was used
for Western blot analysis. Equal amounts of protein were
separated by SDS-PAGE on 4–15% polyacrylamide gels (Bio-
Rad) and transferred to PVDF (Bio-Rad) membranes. Mem-
branes were blocked for 1 h and then incubated overnight
with primary antibody (dilution 1 : 1000) in 5% (w/v) BSA
or milk in TBS-Tween buffer (TBS-T). Blots were washed
in TBS-T 3 times and incubated with HRP-conjugated anti-
rabbit antibody (1 : 5000; Sigma) in 5% (w/v) milk in TBS-
T for 1 h at room temperature (RT). After washing, blots
were developed with ECL (Bio-Rad) following manufac-
turer’s instructions. Primary antibodies used were rabbit
anti-p38 MAPK, rabbit anti-phospho-p38 MAPK, rabbit
anti-ERK1/2 (p44/p42 MAPK), rabbit anti-phospho-ERK1/2
(P44/42 MAPK, T202/Y204), and rabbit anti-phospho-JNK
(T183/Y185) (all Cell Signalling) (𝑛 = 2).
2.6. Metabolite Measurements. Lactate was measured from
cell culture supernatants using a coupled enzymatic assay
in which lactate was oxidised and the resulting H
2
O
2
was
coupled to the conversion of Amplex Red reagent to flu-
orescent resorufin by HRP (horseradish peroxidase). 30 𝜇L
of lactate standard or 200x diluted sample was added to
30 𝜇L of reaction mix. The 30 𝜇L of reaction mix consisted of
0.6 𝜇L of 10U/mL HRP (Sigma), 0.6 𝜇L of 100U/mL lactate
oxidase (Sigma), 0.3 𝜇L of 10mM Amplex Red reagent (Life
Technologies), and 28.5 𝜇L PBS. Samples were incubated for
20min at RT and fluorescence (excitation/emission maxima
= 570/585 nm) was measured on an ELISA reader (BioTek)
(𝑛 = 3 to 5).
Measurements of the NAD+/NADH redox ratio were
adapted from Zhu and Rand [40]. Briefly, 1.5 million stim-
ulated PBMCs were lysed in 75 𝜇L of homogenization buffer
(10mM nicotinamide (Sigma), 10mM Tris-Cl (Sigma), and
0.05% (w/v) Triton X-100 (Sigma), pH 7.4). The lysate
was centrifuged at 12000 g for 1min. From the resulting
supernatants two 18 𝜇L aliquots were removed and either
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Table 1: Primer sequences used for gene expression measurements by qPCR.
Target Forward 5󸀠 → 3󸀠 Reverse 5󸀠 → 3󸀠
h-𝛽2M ATGAGTATGCCTGCCGTGTG CCAAATGCGGCATCTTCAAAC
h-COX-2 CTGGCGCTCAGCCATACAG CGCACTTATACTGGTCAAATCCC
h-CS GGTGGCATGAGAGGCATGAA TAGCCTTGGGTAGCAGTTTCT
h-HDAC1 CCGCATGACTCATAATTTGCTG ATTGGCTTTGTGAGGGCGATA
h-HDAC8 TCGCTGGTCCCGGTTTATATC TACTGGCCCGTTTGGGGAT
h-HIF1-𝛼 GAACGTCGAAAAGAAAAGTCTCG CCTTATCAAGATGCGAACTCACA
h-IDH2 CGCCACTATGCCGACAAAAG ACTGCCAGATAATACGGGTCA
h-IL-10 CAACCTGCCTAACATGCTTCG TCATCTCAGACAAGGCTTGGC
h-IL-1𝛽 GCCCTAAACAGATGAAGTGCTC GAACCAGCATCTTCCTCAG
h-IL12p35 CCTTGCACTTCTGAAGAGATTGA ACAGGGCCATCATAAAAGAGGT
h-IL23p19 CTCAGGGACAACAGTCAGTTC ACAGGGCTATCAGGGAGC
h-MDH2 TCGGCCCAGAACAATGCTAAA GCGGCTTTGGTCTCGATGT
h-SOCS1 TTTTCGCCCTTAGCGTGAAGA GAGGCAGTCGAAGCTCTCG
h-SOCS3 TGCGCCTCAAGACCTTCAG GAGCTGTCGCGGATCAGAAA
h-ST2 TTGTCTACCCACGGAACTACA GCTCTTTCGTATGTTGGTTTCCA
h-TNF-𝛼 CCTCTCTCTAATCAGCCCTCTG GAGGACCTGGGAGTAGATGAG
h-Tollip TGGGCCGACTGAACATCAC GTGGATGACCTTATTCCAGCG
2 𝜇L of 0.2M HCl or 0.2M NaOH was added to each
aliquot. The samples were heated for 30min at 65∘C and
after incubation 2 𝜇L of opposite reagent (NaOH or HCl)
was added to each aliquot. 5 𝜇L of sample or NAD+ (𝛽-
nicotinamide adenine dinucleotide hydrate; Sigma) standard
was then mixed with 85𝜇L of reaction mix and 60 𝜇L of
fluorescence mix in a black 96-well plate. The reaction mix
consisted of 100mMbicine (N,N-bis(2-hydroxyethyl)glycine;
Sigma), 0.6mM ethanol (Sigma), and 5mM EDTA (Life
Technologies). The fluorescence mix consisted of 0.5mM
PMS (phenazine methosulfate; Sigma), 0.05mM resazurin
(Sigma), and 0.2mg ofADH (alcohol dehydrogenase; Sigma).
The reaction was incubated for 15min at RT and fluorescence
(excitation/emission maxima = 540/586 nm) was measured
on an ELISA reader (BioTek) (𝑛 = 3 to 5).
2.7. HDAC Activity Assay. HDAC Fluorometric Cellular
Activity Assay BML-AK503 (FLUOR DE LYS, Enzo Life
Sciences, Inc., Farmingdale, NY) was used to determine
HDAC activity in PBMCs pretreated with C4 (30min) and
then stimulated with H37Rv (30min). Subsequently PBMCs
were incubated with acetylated substrate for 2 hours, after
which a developer was added to generate a fluorescent signal
from the deacetylated substrate. Fluorescence was measured
on a microplate reader (BioTek). Trichostatin A (TSA) was
used as a positive control for HDAC inhibition (𝑛 = 5 to 6).
2.8. Flow Cytometry. PBMCs were treated with 50 𝜇mol C4
for 1 h and stimulated with 1𝜇g/mL H37Rv or 10 ng/mL
LPS for 7 days. Subsequently cells were restimulated with
200𝜇L RPMI supplemented with 10% serum, Golgi-plug
inhibitor (GPI Brefeldin A; 1𝜇g/mL, BD Pharmingen), PMA
(phorbol 12-myristate 13-acetate; 50 𝜇g/mL, Sigma-Aldrich),
and ionomycin (1 𝜇g/mL, Sigma-Aldrich) for 4–6 h at 37∘C
and 5% CO
2
. Cells were then washed with PBA (PBS 1% BSA
(albumin from bovine serum)) and stained extracellularly for
30min with CD4-PeCys7 (ITK) for T-helper 17 (Th17) cells at
4∘C. Next, cells were washed and permeabilized by fix and
perm buffer (eBioscience) according to the manufacturer’s
protocol for 45–60min at 4∘C. Finally cells were washed
and resuspended in 300 𝜇L PBA to be measured using the
Cytomics FC500 (Beckman Coulter) (𝑛 = 8).
Cell death was measured by staining PBMCs with
Annexin V-FITC (BioVision) and Propidium Iodide (PI)
(Invitrogen Molecular Probes). Cells were incubated in
the dark on ice with Annexin-V staining solution (RPMI
supplemented with 5mM CaCl
2
and 0.1 𝜇L/mL Annexin-
V) for 15 minutes. Subsequently PBMCs were stained with
PI for 5 minutes. Cells were measured with the Cytomics
FC500 (Beckman Coulter, Woerden, Netherlands), and data
were analysed using CXP analysis software v2.2 (Beckman
Coulter) (𝑛 = 3 to 5).
2.9. Statistical Analysis. All data were analysed using a
paired nonparametric Wilcoxon signed-rank test, as the data
were not normally distributed. Differences were considered
statistically significant at 𝑝 value < 0.05. Data are shown as
cumulative results of levels obtained in all volunteers (means
± SEM).
3. Results
3.1. Short-Chain Fatty Acids Inhibit Mtb-Induced Cytokine
Responses. DM is associated with altered gut microbiota and
consequently altered SCFA levels [18–22]. In line with current
literature [22, 25–31], we hypothesized that SCFAs have the
potential to influence the host inflammatory response against
Mtb. In particular we investigated the effects of varying
doses of acetate (C2), propionate (C3), and butyrate (C4) on
H37Rv-induced cytokine responses, with RPMI as negative
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control and LPS as positive control (Figure 1). SCFAs them-
selves did not induce cytokine production (results not shown)
but significantly affected H37Rv-induced cytokine release.
C2, C3, and C4 significantly, dose-dependently decreased
H37Rv-induced production of proinflammatory cytokines
TNF-𝛼, IL-1𝛽, and IL-17, while nonsignificant effects were
found for IL-6, IFN-𝛾, and IL-22 production. In contrast, C3
and C4 induced a significant increase in H37Rv-induced pro-
duction of the anti-inflammatory cytokine IL-10. Similarly,
C3 and C4 but not C2 decreased LPS-induced production of
TNF-𝛼 and IL-6, while the release of IL-1𝛽 was significantly
decreased in response to all three SCFAs (results not shown).
LPS did not induce production of IFN-𝛾, IL-17, or IL-
22. Moreover, all three SCFAs incurred a dose-dependent,
nonsignificant decrease in LPS-induced IL-10 production
(results not shown).
Overall, C4 resulted in some of the most significant
changes in cytokine responses (Figure 1(b)). Moreover, the
potency of butyrate in reducing cytokine responses to H37Rv
and LPS was greater than that for the other SCFAs. Impor-
tantly, changes in cytokine levels could not be explained
by altered pH levels or cell death (Supplementary Figure
1 A and B in Supplementary Material available online at
http://dx.doi.org/10.1155/2016/6014631). Therefore, following
this screen, we continued our study with C4 at a concentra-
tion of 50𝜇M, which is physiologically relevant because it is
comparable to human plasma concentrations [39].
3.2. Influence of Butyrate on HDAC Expression and Activity.
Butyrate is reported to be a strongHDAC inhibitor. Since this
might account for its anti-inflammatory effects [41–44], we
examined the effect of C4 on HDAC expression and activity.
C4 significantly decreased HDAC8 but not HDAC1 gene
expression upon H37Rv stimulation of PBMCs (Figure 2(a)).
Consistent with previous reports [36, 42–44], C4 at a high
dose of 1mM decreased HDAC activity upon both RPMI
and H37Rv stimulation. However, different from its effect
on gene expression, C4 at a physiological dose of 50 𝜇M
had no effect on actual HDAC activity (Figure 2(b)), while
trichostatin A (TSA, positive control) strongly decreased
HDAC activity. These data suggest that butyrate’s inhibition
of HDAC activity is unlikely to play a role in the effects of
low doses of C4 onMtb-induced inflammatory responses and
stresses the importance of studying the effects of butyrate at
physiologically relevant concentrations.
3.3. The Effects of Butyrate on TLR-Signalling Mediators
and the Eicosanoid Pathway. Signalling of Toll-like receptors
(TLRs), important receptors for Mtb recognition [45–47],
is controlled by feedback mechanisms regulated by several
intracellular kinases [48, 49]. Because impaired Mtb recog-
nition and insufficient TLR signalling may account for the
anti-inflammatory effects of C4, we examined whether C4
affected these feedback loops. However, C4 had no effect on
phosphorylation of the MAP kinases p38, ERK (Figure 3(a)),
or JNK (Supplementary Figure 2). C4 has also been reported
to induce expression of inhibitors of TLR signalling pathways
[50], but we found that C4 significantly decreased mRNA
expression of TLR signalling inhibitors SOCS1 and Tollip
and did not affect expression of SOCS3 or ST2 (Figure 3(b)).
Of note, these results were not explained by cell death
(Supplementary Figure 1 B).
Aside from TLR signalling, C4 possibly exerts its anti-
inflammatory effects through modulation of the eicosanoid
pathway. Eicosanoids, oxygenatedmetabolites of arachidonic
acid, modulate the host immune response to Mtb [51–55].
C4 has been reported to upregulate key enzymes of the
eicosanoid pathway upon LPS stimulation [30], but a reverse
effect has also been described [56]. We did not observe a
significant impact of C4 on transcript levels of cyclooxyge-
nase 2 (COX-2), one of the main eicosanoid enzymes, upon
H37Rv or LPS stimulation (Supplementary Figure 3A).Alter-
natively, C4 has been described to induce release of the anti-
inflammatory prostaglandin PGE
2
[26, 30, 57]. Inhibition of
PGE
2
with aspirin could not counteract the inhibitory effects
of C4 on TNF-𝛼 and IL-1𝛽 cytokine responses upon either
H37Rv or LPS stimulation (Supplementary Figure 3 B). The
eicosanoid pathway is therefore unlikely to be the mediator
pathway through which C4 exerts its anti-inflammatory
effects.
3.4. Influence of Butyrate on Cellular Metabolism. Another
possible explanation for butyrate’s anti-inflammatory effects
is its influence on cellular metabolism. A recent paper
described that microbiota have a strong effect on energy
homeostasis in the mammalian colon and showed that C4
regulates different aspects of energy metabolism acting as an
important energy source for colonocytes [58]. Contrary to
this previous study, we observed no effects of C4 on cellular
lactate production, the NAD+/NADH redox ratio, TCA cycle
gene expression (Figure 4), or 𝛽-oxidation (Supplementary
Figure 4). These data strongly suggest that C4 modulates
the immune response to Mtb independently of cellular
metabolism.
3.5. Butyrate Transcriptionally Influences Cytokine Responses
to Mtb, Possibly Mediated through IL-10 Induction. We next
examined whether the inhibitory effect of C4 on Mtb-
induced proinflammatory cytokine responses, with a con-
comitant increase in anti-inflammatory IL-10 production
(Figure 1) and decrease inTh17 proliferation (Supplementary
Figure 5 A), was also present at the level of gene tran-
scription. C4 led to a decrease in TNF-𝛼, IL-12, and IL-
23 mRNA levels upon H37Rv stimulation and a parallel
increase in IL-10 mRNA (Figure 5(a)), while no effect on
production of the anti-inflammatory cytokine IL-1Ra was
observed (Supplementary Figure 5 B). These data point
to IL-10 as a possible intermediary mediator of the anti-
inflammatory effects of C4. We therefore assessed whether
removing IL-10 protein from the cellular environment could
counteract the inhibitory effects of C4. To this end, we
pretreated PBMCs with cycloheximide (CHX), an inhibitor
of translation. Stimulation of PBMCs with H37Rv in the
presence of C4 in combination with CHX resulted in higher
TNF-𝛼 responses, as compared to incubation with H37Rv
and C4 alone. Upon LPS stimulation, this effect was not
present (Figure 5(b)). We subsequently examined whether
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Figure 1: Short-chain fatty acids inhibit Mtb-induced cytokine responses. (a) PBMCs were preincubated with 2–250 𝜇M SCFAs for 1 h prior
to stimulation with Mtb lysate for 24 h and 7 d. Hereafter TNF-𝛼, IL-6, IL-10, IFN-𝛾, IL-17, and IL-22 were measured in supernatants by
ELISA. Data are means ± SEM (𝑛 = 6), using Wilcoxon signed-rank test, representative of 2 independent experiments. ∗𝑝 < 0.05. (b) Heat
map of log-transformed mean cytokine responses as measured by ELISA, showing cytokines upregulated (red) and downregulated (blue)
upon H37Rv stimulation in the presence of different doses of SCFAs. Cytokine responses are shown as compared to H37Rv stimulation alone.
∗𝑝 < 0.05.
blocking IL-10 specifically using an anti-IL-10 antibody could
counteract the inhibitory effects of C4 on proinflammatory
cytokine response. Blocking IL-10 completely restored IL-6
cytokine responses in response toH37Rv and C4, while TNF-
𝛼 and IL-1𝛽 productionwas partly restored (Figure 5(c)).This
suggests an important role for intermediary protein synthesis,
specifically IL-10, in mediating the anti-inflammatory effects
of C4.
4. Discussion
DM is associated with a threefold increased risk of active
TB, but the underlying immunological mechanisms remain
largely unknown [3, 12, 13]. Alterations in the gut microbiota
of DM patients are associated with changes in plasma SCFA
concentrations. Multiple papers have reported a decrease in
C4-producing bacteria in type 2 DM patients [18, 19, 21,
23, 24]. We here show that SCFAs, especially C4, exhibit
anti-inflammatory properties; low doses of C4 decreased
Mtb-induced proinflammatory cytokine responses on both
the transcriptional level and the translational level, while
production of IL-10 was increased. This anti-inflammatory
effect was independent of HDAC activity, Toll-like receptor
signalling, the eicosanoid pathway, or cellular metabolism.
We observed a general anti-inflammatory effect of C2, C3,
and C4 on Mtb-induced cytokine production. C4 induced
some of the most significant and most potent changes in
cytokine responses, which is in line with published results
[29], although our study is the first to examine the effects
of physiological concentrations of SCFAs on Mtb-induced
cytokine responses in vitro. Several observations were made
regarding the effect of SCFA on cytokines. Firstly, the
inhibitory effect of all three SCFAs on production of TNF-
𝛼 and IL-1𝛽 was comparable for Mtb and LPS stimulation.
However, while C3 and C4 had a clear effect on LPS-induced
IL-6 release, this was not found for Mtb. This suggests that
SCFAs do not affect Mtb-induced IL-6, although IL-6 has
been assigned an important role in Mtb host responses
[59–62]. Secondly, C2, C3, and C4 had a much stronger
inhibitory effect on T-cell derived cytokine IL-17 than on
T-cell derived cytokines IFN-𝛾 and IL-22. Because C4 also
strongly decreasedTh17 proliferation (Supplementary Figure
5 A), SCFAs may affect Th17 subsets more than other T-cell
subsets. This may be of great relevance since Th17 cells, and
IL-17 in particular, have been reported to be essential in pro-
tective immunity againstMtb [63, 64] but inversely associated
withDM complications [65–67]. Lastly, the stimulatory effect
of C3 and C4 on anti-inflammatory IL-10 release was Mtb-
specific and was not seen with LPS stimulation. IL-10 has
Journal of Diabetes Research 7
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Figure 2: Influence of butyrate on HDAC expression and activity. (a) PBMCs were preincubated with 50 𝜇M C4 for 1 h prior to stimulation
withMtb lysate or LPS for 4 h. Gene expression levels of HDAC1 andHDAC8weremeasured by qPCR. Data aremeans ± SEM (𝑛 = 10), using
Wilcoxon signed-rank test, representative of 3 independent experiments. ∗𝑝 < 0.05. (b) Percentage of general HDAC activity relative to RPMI
stimulated PBMCs, as measured by levels of substrate deacetylation after 30min of preincubation with C4 (50𝜇M) and 30min of stimulation
withMtb lysate. Data aremeans± SEM (𝑛 = 5 to 6), usingWilcoxon signed-rank test, representative of 3 independent experiments. ∗𝑝 < 0.05.
been delineated as an important mediator in Mtb infection:
it has been reported to block bacterial killing inMtb-infected
macrophages, suppress multinucleated giant cell formation
and cytokine production, and inhibit the development of
protective immunity [68–74]. In contrast to TB, IL-10 may
have a protective role in type 2 DM by reducing insulin
resistance and obesity [75–77]. Therefore, the increase in IL-
10 production we see as induced by C4 is very relevant for the
course of both DM and TB disease.
We examined several possible mechanisms underlying
the effect of C4 on cytokine production, starting with HDAC
activity, which is known to be inhibited by SCFAs. C4 at
a physiological low dose of 50 𝜇M had little effect, while
millimolar concentrations of C4 (as used in other studies [36,
41–44]) decreased HDAC activity upon H37Rv stimulation.
This is expected as IC
50
values of HDAC inhibition by
C4 are >100𝜇M, depending on the class of HDAC [43].
The strongest effect was noted for HDAC8, which is reported
to be most sensitive to C4 [43].This argues that physiological
C4 concentrations in humanplasmadonot exertHDAC inhi-
bition and underlines the importance of using physiological
concentrations within in vitro experimental models.
In contrast to a previous study [50], we observed a
decreased gene expression of the TLR modulatory factors
SOCS1 and Tollip when PBMCs were stimulated in the
presence of C4, which thus cannot explain the inhibitory
effects on cytokine production. This, together with our data
showing that C4 does not affectMAP kinase activity, suggests
that C4 does not act at the level of TLR signalling, as shown
previously [36].
As a third possible mechanism, we assessed whether
C4 exerts its effects through eicosanoid metabolism. The
eicosanoid pathway is under influence of SCFAs [30, 56] and
may modulate the host response to Mtb [51–55]. C4 did not
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Figure 3: The effects of butyrate on TLR signalling mediators. (a) PBMCs were preincubated with 50 𝜇M C4 (1 h) and stimulated with
Mtb lysate or LPS. Cell lysates were harvested at 30min after stimulation. Phospho-p38, p38, phospho-ERK, and ERK protein levels were
determined by Western blot using specific antibodies (𝑛 = 2). (b) Gene expression levels of SOCS1, SOCS3, ST2, and Tollip in PBMCs
preincubated with 50 𝜇M C4 (1 h) and stimulated with Mtb lysate or LPS (4 h) as measured by qPCR. The box plot represents median with
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3 independent experiments. ∗𝑝 < 0.05.
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Figure 5: Butyrate transcriptionally influences cytokine responses to Mtb, possibly mediated through IL-10. (a) Cytokine gene expression
levels in PBMCs preincubated with 50𝜇MC4 for 1 h prior to stimulation with Mtb lysate or LPS for 4 h, as measured by qPCR. The box plot
represents median with first and third quartiles; the whiskers represent minimum and maximum values. 𝑛 = 6 to 10, usingWilcoxon signed-
rank test, representative of 2+ independent experiments. ∗𝑝 < 0.05. (b) To block translation, PBMCs were preincubated with cycloheximide
(CHX) for 1 h prior to 1 h incubation with C4 (50𝜇M). TNF-𝛼 transcript levels were measured by qPCR 4 h after stimulation with Mtb lysate
or LPS. Data are single values (𝑛 = 6 to 7), using Wilcoxon signed-rank test, representative of 3 independent experiments. ∗𝑝 < 0.05. (c)
To block IL-10 activity, PBMCs were preincubated with IL-10 and C4 (50𝜇M) for 1 h. IL-6, TNF-𝛼, and IL-1𝛽 production was measured by
ELISA after 24 h of stimulation with Mtb lysate. Data are means ± SEM (𝑛 = 10 to 12), using Wilcoxon signed-rank test, representative of 4
independent experiments.
affect expression of COX-2, a key enzyme in the eicosanoid
pathway, in contrast to previous reports that used supraphys-
iological C4 concentrations [30, 56]. In addition, inhibition of
the eicosanoid pathway using aspirin did not counteract the
effects of C4.Therefore, the eicosanoid pathway is unlikely to
be involved in mediating the effects of C4.
The effect of diabetes on the host immune response to
Mtb might also be explained by altered cellular metabolism,
with a possible role for SCFA. Cellular metabolism is increas-
ingly linked to immunology [78–80]. One previous study
noted that C4 influences metabolic processes in colonocytes
[58], which use butyrate as their primary energy source [58].
However, we did not observe any effect of C4 on lactate
production, the redox status, TCA cycle gene expression, or
𝛽-oxidation in PBMCs. We therefore conclude that cellular
metabolism does not mediate the effect of C4 on Mtb-
induced cytokine production.
Finally, we further examined the effect of C4 on the
anti-inflammatory cytokine IL-10. IL-10 is detrimental to
TB outcome, while it may improve DM symptoms [68–
77]. In line with previous studies [33, 81, 82], we report an
upregulation in IL-10 production induced by C4. Removal
of all intermediary protein, including IL-10, from PBMCs
stimulated with H37Rv and C4 led to a significant increase
in TNF-𝛼 transcript, thereby counteracting the decrease
in TNF-𝛼 production induced by C4. Moreover, blocking
IL-10 specifically fully restored IL-6 responses in PBMCs
stimulated with H37Rv and C4 and partly restored TNF-
𝛼 and IL-1𝛽 responses. These data suggest that the anti-
inflammatory cytokine IL-10 may play a role in the inhibitory
effects of C4 on Mtb-induced inflammatory responses.
Currently, much research focuses on modulation of the
gut microbiota in order to treat obesity and type 2 DM [83–
86]. Administration of sodium butyrate or butyrate-inducing
probiotics in mice significantly increased plasma insulin
levels and insulin sensitivity and suppressed bodyweight gain
[87–89]. The anti-inflammatory effects of C4 may attenuate
the chronic inflammatory state associated with type 2 DM,
thereby improving DM symptoms. If chronic inflammation
is a causal factor of the impaired host response toMtb in type
2 DM patients, attenuation of this hyperinflammatory state
may improve not only DM but also TB outcome in patients
with coincident DM and TB disease.
Some limitations of our study need to be addressed.
Firstly, we studied the effects of C4 on Mtb-induced inflam-
mation in PBMCs in vitro. SCFA levels have been shown to be
altered in DM patients [18–22], but this in vitro model does
not include other aspects of the pathophysiology of DM such
as hyperglycemia, hyperinsulinemia, or dyslipidemia, phe-
nomena which have also been reported to affect immunity
[90–94]. Furthermore, DM medications possibly interfere
with the intestinal microbiota and immune responses in
patients [95–97]. It is therefore unclear how accurately our
in vitromodel reflects the in vivo situation in DM patients.
In conclusion, we show an anti-inflammatory effect of
low, physiological doses of C4 onMtb-induced inflammatory
responses. The anti-inflammatory cytokine IL-10 may play
a role in mediating the inhibitory effects of C4 on the host
immune response to Mtb. Further studies are needed to
precisely explore the pathways by which physiological con-
centrations of C4 exert their anti-inflammatory effects and to
define the mechanism of increased TB sensitivity in type 2
DM patients. Moreover, current research on modulating gut
microbiota in DM should include its possible effects on TB.
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